OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

Jia, Zhenhong; Shi, Ling-Fei; Wang, Zheng; Li, Min; Zhang, Jin-Seng; Mao, Ying; Wang, Hua

doi:10.1016/j.clinsp.2022.100120

Cited by 4 publications

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature

Lizunou,

Potthoff,

Schäfer

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The rarity of cerebellar glioblastoma presents a significant challenge in clinical practice due to the lack of extensive prognostic data on long-term survival rates, rendering it an underrepresented entity compared to its supratentorial counterpart. This study aims to analyze potential differences in survival outcome between patients with cerebellar and supratentorial glioblastomas. Methods From 2009 to 2020, 8 patients underwent surgical treatment for cerebellar glioblastoma at the authors’ institution. These patients were individually matched with a cohort of 205 consecutive patients from our institutional database with supratentorial glioblastoma, taking into account key prognostic parameters. Progression-free survival (PFS) and overall survival (OS) rates were compared. Additionally, we performed a systematic literature review to compile further survival data on cerebellar glioblastoma patients. Results The median OS for cerebellar glioblastoma patients was 18 months (95% CI 11–25). The balanced matched-pair analysis showed no significant difference in survival when compared to patients with supratentorial glioblastoma, exhibiting a median OS of 23 months (95% CI 0–62) (p = 0.63). Respective values for PFS were 8 months (95% CI 4–12) for cerebellar and 7 months (95% CI 0–16) for supratentorial glioblastoma (p = 0.2). The systematic review revealed that median OS for cerebellar glioblastoma in current literature ranges from 7 to 21 months. Conclusions The present findings indicate that patients with supra- and infratentorial glioblastoma do not significantly differ in regard to survival outcome parameters. This similarity in prognosis might encourage clinicians to consider surgical interventions for both supra- and infratentorial glioblastoma in a similar manner.

show abstract

Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature

Lizunou,

Potthoff,

Schäfer

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment

Khot,

Krishnaveni,

Gharat

et al. 2024

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis

Li,

Yun,

Huang

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Gliomas are the most common primary central nervous system neoplasm. Despite recent advances in the diagnosis and treatment of gliomas, patient prognosis remains dismal. Therefore, it is imperative to identify novel diagnostic biomarkers and therapeutic targets of glioma to effectively improve treatment outcomes. AIM To investigate the association between oligodendrocyte transcription factor 2 (Olig2) expression and the outcomes of glioma patients. METHODS The PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure databases were searched for studies (published up to October 2023) that investigated the relationship between Olig2 expression and prognosis of glioma patients. The quality of the studies was assessed using the Newcastle Ottawa Scale. Data analyses were performed using Stata Version 12.0 software. RESULTS A total of 1205 glioma patients from six studies were included in the meta-analysis. High Olig2 expression was associated with better outcomes in glioma patients [hazard ratio (HR): 0.81; 95% (confidence interval) CI: 0.51-1.27; P = 0.000]. Furthermore, the results of subgroup meta-analysis showed that high expression of Olig2 was associated with poor overall survival in European patients (HR: 1.34; 95%CI: 0.79-2.27) and better prognosis in Asian patients (HR: 0.43; 95%CI: 0.22-0.84). The sensitivity analysis showed that no single study had a significant effect on pooled HR, and there was also no indication of publication bias according to the Egger’s and Begger’s P value test or funnel plot test. CONCLUSION High Olig2 expression may have a positive impact on the prognosis of glioma patients, and should be investigated further as a prognostic biomarker and therapeutic target for glioma.

show abstract

OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

Cited by 4 publications

References 31 publications

Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature

Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature

Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment

Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis

Contact Info

Product

Resources

About